Orphan Biosimilars: Developers See Big Prospects In Small Markets; Soliris Is One Target
Using lessons learned from the first wave of biosimilar approvals – and citing high prices in the US – some developers are starting to 'think small' with biosimilars for rare disease markets. Alexion’s Soliris is a case in point.
You may also be interested in...
Hard-won experience from the first wave of broad-market biosimilars will inform development of "orphan biosimilars," but Navigant Consulting says that biopharmas entering this orphan market will face a unique set of challenges.
Anand Shah returns to FDA as deputy commissioner; like Abernethy, he is an oncologist with a background in big data.
Resubmission comes more than four years after Purdue pulled an sNDA seeking to demonstrate ‘real-world’ abuse prevention.